Mga Batayang Estadistika
| LEI | 5493000845S6RLSDWJ40 |
| CIK | 1626199 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Alpine Immune Sciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| November 14, 2024 |
ALPN / Alpine Immune Sciences, Inc. / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-alpn093024a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* ALPINE IMMUNE SCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 02083G100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-37449 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specifi |
|
| May 21, 2024 |
SC 13D/A 1 tm2415095d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) Decheng Capital China Life Sciences USD Fund III, L.P. Ugland House, |
|
| May 21, 2024 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G 100 (CUSIP Number) Steve R. Bailey Frazier Life Sciences 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and |
|
| May 20, 2024 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ALPINE IMMUNE SCIENCES, INC. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALPINE IMMUNE SCIENCES, INC. FIRST: The name of the corporation is Alpine Immune Sciences, Inc. (the “Corporation”). SECOND: The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, 19801. The name of its registered agent at that address is The Co |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ALPINE IMMUNE SCIENCES, INC. A Delaware Corporation Effective May 20, 2024 TABLE OF CONTENTS Page ARTICLE I OFFICES Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings 1 Section 2. Annual Meetings 2 Section 3. Special Meetings 2 Section 4. Notice 2 Section 5. Adjournments and Po |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) ALPINE IMMUNE SCIENCES, INC. (Name of Subject Company (Issuer)) ADAMS MERGER SUB, INC. (Offeror) a wholly owned subsidiary of VERTEX PHARMACEUTICALS INCORPORATED (Parent of Offeror) (Names of Filing Pe |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Alpine Immune Sciences, Inc. (Name of Subject Company) Alpine Immune Sciences, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 ALPINE IMMUNE SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37449 20-8969493 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Alpine Immune Sciences, Inc. (Name of Subject Company) Alpine Immune Sciences, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of |
|
| May 10, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) ALPINE IMMUNE SCIENCES, INC. (Name of Subject Company (Issuer)) ADAMS MERGER SUB, INC. (Offeror) a wholly owned subsidiary of VERTEX PHARMACEUTICALS INCORPORATED (Parent of Offeror) (Names of |
|
| May 9, 2024 |
Alpine Immune Sciences Reports First Quarter 2024 Financial Results Exhibit 99.1 Alpine Immune Sciences Reports First Quarter 2024 Financial Results SEATTLE, Washington - May 9, 2024 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Ph |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commissio |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IM |
|
| May 8, 2024 |
Slide Excerpts from Vertex Q1 Earnings Call Presentation on May 6, 2024. Exhibit 99.(a)(5)(E) FIRST QUARTER 2024 FINANCIAL RESULTS MAY 6, 2024 ©2024 Vertex Pharmaceuticals Incorporated SAFE HARBOR STATEMENT & NON-GAAP FINANCIAL MEASURES This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, in |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) ALPINE IMMUNE SCIENCES, INC. (Name of Subject Company (Issuer)) ADAMS MERGER SUB, INC. (Offeror) a wholly owned subsidiary of VERTEX PHARMACEUTICALS INCORPORATED (Parent of Offeror) (Names of Filing Pe |
|
| May 8, 2024 |
Transcript of Vertex Q1 Earnings Call on May 6, 2024. EX-99.(a)(5)(F) Exhibit 99.(a)(5)(F) ● Event Details Date: 2024-05-06 Company: Vertex Pharmaceuticals, Inc. Ticker: VRTX-US ● Company Participants Susie Lisa - Vertex Pharmaceuticals, Inc., Senior Vice President-Investor Relations Reshma Kewalramani - Vertex Pharmaceuticals, Inc., President, Chief Executive Officer & Director Stuart A. Arbuckle - Vertex Pharmaceuticals, Inc., Executive Vice Presid |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Alpine Immune Sciences, Inc. (Name of Subject Company) Alpine Immune Sciences, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) Decheng Capital China Life Sciences USD Fund III, L.P. Ugland House, PO Box 309, Grand Cayman KY1-1104, Cayman |
|
| April 29, 2024 |
SC 13D/A 1 d790376dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G 100 (CUSIP Number) Steve R. Bailey Frazier Life Sciences 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (20 |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37449 ALPINE I |
|
| April 22, 2024 |
Mutual Confidentiality Agreement, dated March 21, 2024, between Alpine and Vertex. Exhibit (d)(5) Execution Copy MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (this “Agreement”) is entered into as of March 21, 2024, by and between Vertex Pharmaceuticals Incorporated (‘‘you”) and Alpine Immune Sciences, Inc. |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Alpine Immune Sciences, Inc. (Name of Subject Company) Alpine Immune Sciences, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 02083 |
|
| April 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables SCHEDULE TO ALPINE IMMUNE SCIENCES, INC. |
|
| April 22, 2024 |
Summary Advertisement, as published in The New York Times on April 22, 2024 Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| April 22, 2024 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of ALPINE IMMUNE SCIENCES, INC. |
|
| April 22, 2024 |
Mutual Confidentiality Agreement, dated February 14, 2024, between Alpine and Vertex. Exhibit (d)(4) MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (this “Agreement”) is made effective as of the date of the last signature below (the “Effective Date”), by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with offices at 50 Northern Avenue, Boston, Massachusetts 02210 (“Vertex”) and Alpine Immune Sciences, Inc. |
|
| April 22, 2024 |
Offer to Purchase, dated April 22, 2024 Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of ALPINE IMMUNE SCIENCES, INC. |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ALPINE IMMUNE SCIENCES, INC. (Name of Subject Company (Issuer)) ADAMS MERGER SUB, INC. (Offeror) a wholly owned subsidiary of VERTEX PHARMACEUTICALS INCORPORATED (Parent of Offeror) (Names of Filing Persons (identifying |
|
| April 22, 2024 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ALPINE IMMUNE SCIENCES, INC. |
|
| April 22, 2024 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ALPINE IMMUNE SCIENCES, INC. |
|
| April 11, 2024 |
Transcript of Investor Presentation Call on April 10, 2024. Exhibit 99.1 APRIL 10, 2024 / 8:30PM, VRTX.OQ - Vertex Pharmaceuticals Inc Enters Into Agreement to Acquire Alpine Immune Sciences- Conference Call CORPORATE PARTICIPANTS Charles F. Wagner Vertex Pharmaceuticals Incorporated - Executive VP & CFO Jeffrey Marc Leiden Vertex Pharmaceuticals Incorporated - Executive Chairman Reshma Kewalramani Vertex Pharmaceuticals Incorporated - CEO, President & Dir |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Alpine Immune Sciences, Inc. (Name of Subject Company (issuer)) Adams Merger Sub, Inc. (Offeror) a wholly-owned subsidiary of Vertex Pharmaceuticals Incorporated (Parent of Offeror) (Names of Filing Persons (identifying |
|
| April 10, 2024 |
Email to Alpine Service Providers [including contractors embedded with our staff, i.e., HR, IT] Exhibit 99.1 Email to Alpine Service Providers [including contractors embedded with our staff, i.e., HR, IT] Colleagues, Earlier today, we announced that Alpine Immune Sciences has entered into a definitive agreement to be acquired by Vertex Pharmaceuticals Incorporated. Below is the email Mitch sent to employees announcing this news. As a key member of the Alpine team, we wanted to confirm that o |
|
| April 10, 2024 |
EX-99.1 EXHIBIT 99.1 Vertex Enters Into Agreement to Acquire Alpine Immune Sciences - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept holds promise as a |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Alpine Immune Sciences, Inc. (Name of Subject Company) Alpine Immune Sciences, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 02083 |
|
| April 10, 2024 |
EX-10.1 EXHIBIT 10.1 EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of April 10, 2024, is entered into by and among Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Parent”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and each of the stockholders of Alpine Im |
|
| April 10, 2024 |
Exhibit 99.3 CONFIDENTIAL DRAFT Investor FAQ 1. When will more information about the transaction and negotiations be available? Vertex Pharmaceuticals Incorporated (“Vertex”) will initiate the tender offer process with a public filing of a tender offer document, and Alpine Immune Sciences, Inc. (“Alpine”) will make its own public filing at the same time. Please review these documents for additiona |
|
| April 10, 2024 |
EX-10.2 EXHIBIT 10.2 EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of April 10, 2024, is entered into by and among Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Parent”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), each of the stockholders of Alpine Immune |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 10, 2024 |
EX-99.1 EXHIBIT 99.1 Vertex Enters Into Agreement to Acquire Alpine Immune Sciences - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept holds promise as a |
|
| April 10, 2024 |
Exhibit 99.2 CONFIDENTIAL DRAFT Employee FAQ—To be posted on April 10, 2024 after AEM 1. What was announced today? Vertex Pharmaceuticals Incorporated (“Vertex”) and Alpine Immune Sciences, Inc. (“Alpine”) announced an agreement for the acquisition of Alpine for $65.00 per share, or approximately $4.9 billion. 2. Why does Vertex want to acquire Alpine? Vertex was looking for opportunities to expan |
|
| April 10, 2024 |
Alpine Investor Webcast April 10, 2024 Exhibit 99.4 Disclaimers Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements, including about the proposed acquisition of Alpine Immune Sciences, Inc. (Alpine) by Vertex Pharmaceuticals Incorporated (Vertex). These forward-looking statements are not based on historical fact and include statement |
|
| April 10, 2024 |
Investor Presentation, dated April 10, 2024. Exhibit 99.2 VERTEX PHARMACEUTICALS ACQUISITION OF ALPINE IMMUNE SCIENCES APRIL 10, 2024 ©2024 Vertex Phag rlm oba acle .v uti rtx c.a clo s m Incorporated This presentation contains forward-looking statements related to Vertex, Alpine and the proposed acquisition of Alpine by Vertex (the “Transaction”) that are subject to risks, uncertainties and other factors. While Vertex believes the forward-l |
|
| April 10, 2024 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Alpine Immune Sciences, Inc. (Name of Subject Company) Alpine Immune Sciences, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securitie |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Alpine Immune Sciences, Inc. (Name of Subject Company (issuer)) Adams Merger Sub, Inc. (Offeror) a wholly-owned subsidiary of Vertex Pharmaceuticals Incorporated (Parent of Offeror) (Names of Filing Persons (identifying |
|
| April 10, 2024 |
EX-99.2 Exhibit 99.2 Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy — Povetacicept administered subcutaneously once every four weeks continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 weeks, associated with remission, resolution of hematuria, and stable renal function (eGFR) — — Company reports succes |
|
| April 10, 2024 |
EX-2.1 EXHIBIT 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER DATED AS OF APRIL 10, 2024, AMONG VERTEX PHARMACEUTICALS INCORPORATED, ADAMS MERGER SUB, INC. AND ALPINE IMMUNE SCIENCES, INC. Table of Contents Page ARTICLE I DEFINITIONS 2 SECTION 1.01 Definitions 2 SECTION 1.02 Interpretation and Rules of Construction 10 ARTICLE II THE OFFER 11 SECTION 2.01 The Offer 11 SECTION 2.02 Company Actio |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 20, 2024 |
Non-Employee Director Compensation Guidelines Exhibit 10.6 Alpine Immune Sciences, Inc. Non-Employee Director Compensation Guidelines As amended December 5, 2023 The purpose of these Non-Employee Director Compensation Guidelines (the “Guidelines”) of Alpine Immune Sciences, Inc., a Delaware corporation the (the “Company”), is to provide a total compensation package that enables the Company to attract, retain and reward, on a long-term basis, |
|
| March 20, 2024 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Alpine Immune Sciences, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. The general terms and provisions of our common stock are summarized below. This summary d |
|
| March 20, 2024 |
As filed with the Securities and Exchange Commission on March 20, 2024 Registration No. |
|
| March 20, 2024 |
Exhibit 10.26 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [***]. December 20, 2023 Alpine Immune Sciences Inc. 188 E Blaine St Suite 200 Seattle, WA 98102 United States Attention: Paul Rickey, CFO Re: The Option and License Agreement between Alpin |
|
| March 20, 2024 |
As filed with the Securities and Exchange Commission on March 20, 2024 Registration No. |
|
| March 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Alpine Immune Sciences, Inc. |
|
| March 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Alpine Immune Sciences, Inc. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37449 ALPINE IMMUNE SCIENCES, IN |
|
| March 20, 2024 |
Exhibit 97 ALPINE IMMUNE SCIENCES, INC. COMPENSATION RECOVERY POLICY As adopted on November 27, 2023 Alpine Immune Sciences, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commis |
|
| March 18, 2024 |
Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results - Clinical data on povetacicept in IgA nephropathy will be updated at the upcoming WCN meeting, including follow up at 80 mg and initial data at 240 mg SC once every four-weeks - - Povetacicept advancing towards a pivotal phase 3 trial in IgA nephropathy and a phase 2 trial in systemic lupus erythema |
|
| February 14, 2024 |
ALPN / Alpine Immune Sciences, Inc. / Omega Fund VI, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d783272dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3) Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G100 (CUSIP Number) D |
|
| February 14, 2024 |
ALPN / Alpine Immune Sciences, Inc. / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-alpn123123a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALPINE IMMUNE SCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement |
|
| February 14, 2024 |
Exhibit 1: Joint filing agreement EX-99.1 2 tm246065d2ex1.htm EXHIBIT1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission |
|
| February 14, 2024 |
ALPN / Alpine Immune Sciences, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2024 |
ALPN / Alpine Immune Sciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALPINE IMMUNE SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this State |
|
| February 14, 2024 |
ALPN / Alpine Immune Sciences, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm245955d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this stateme |
|
| February 14, 2024 |
SC 13G/A 1 p24-0770sc13ga.htm ALPINE IMMUNE SCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| February 7, 2024 |
Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 5, 2024 |
Change of Control and Severance Policy, as amended Exhibit 10.1 Alpine Immune Sciences, Inc. Change of Control and Severance Policy This Change of Control and Severance Policy (the “Policy”), as amended and restated effective January 4, 2024 (the “Effective Date”), is designed to provide certain protections to a select group of key employees of Alpine Immune Sciences, Inc. (“Alpine” or the “Company”) or any of its subsidiaries in connection with a |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 29, 2023 |
EX-99.1 2 ss2864243ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 8 to the Statement on Schedule 13D, dated December 28, 2023, with respect to the common stock of Alpine Immune Sciences, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 193 |
|
| December 29, 2023 |
ALPN / Alpine Immune Sciences, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 8 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G100 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) |
|
| December 21, 2023 |
Exhibit 99.1 Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie - Enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus (Synergy) will be stopped to allow for early assessment of data - - Final analysis after last patient completes study protocol expected to occur by the end of 2024 - SEATTLE, Washington, December 21, 2023 |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 22, 2023 |
SC 13D/A 1 d550723dsc13da.htm SC 13D/A NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G 100 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 Te |
|
| November 14, 2023 |
-Alone Inducement Stock Option Grant between the Registrant Exhibit 10.2 ALPINE IMMUNE SCIENCES, INC. STAND-ALONE INDUCEMENT STOCK OPTION GRANT NOTICE OF GRANT OF STOCK OPTION This grant (the “Option”) shall be governed by this Notice of Grant of Stock Option (the “Notice of Grant”) and the Terms and Conditions of Stock Option Grant (the “Terms and Conditions”), attached hereto as Exhibit A (together, the “Agreement”). Terms not otherwise defined in the No |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPIN |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Com |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) Decheng Capital China Life Sciences USD Fund III, L.P. Ugland House, PO Box 309, Grand Cayman KY1-1104, Cayman |
|
| November 14, 2023 |
dated as of September 20, 2023, by and between the R Exhibit 10.1 ALPINE IMMUNE SCIENCES, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into between Alpine Immune Sciences, Inc. (the “Company”), and Wolfgang Dummer (“Executive”) (collectively referred to as the “Parties” or individually as a “Party”). R E C I T A L S WHEREAS, the Company desires to employ Executive as its Chief Medical Officer ( |
|
| November 14, 2023 |
Exhibit 99.1 Alpine Immune Sciences Reports Third Quarter 2023 Financial Results - First clinical data with povetacicept presented at American Society of Nephrology Kidney Week support best-in-class potential and broad pipeline opportunity – - Company closed an oversubscribed $150 million equity offering to accelerate multiple development activities – - Multiple catalysts with povetacicept targete |
|
| November 14, 2023 |
ALPN / Alpine Immune Sciences Inc / Alpine ImmunoSciences, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d315803dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) Dr. Mitchell H. Gold 600 Stewart Street, Suite 1503 Seattle, Washington 98101 Telephon |
|
| November 14, 2023 |
Form of Stand-Alone Inducement Stock Option Grant Exhibit 10.3 ALPINE IMMUNE SCIENCES, INC. STAND-ALONE INDUCEMENT STOCK OPTION GRANT NOTICE OF GRANT OF STOCK OPTION This grant (the “Option”) shall be governed by this Notice of Grant of Stock Option (the “Notice of Grant”) and the Terms and Conditions of Stock Option Grant (the “Terms and Conditions”), attached hereto as Exhibit A (together, the “Agreement”). Terms not otherwise defined in the No |
|
| November 13, 2023 |
ALPN / Alpine Immune Sciences Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 7 Activist Investment SC 13D/A 1 ss2696773sc13da.htm AMENDMENT NO. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G100 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC 601 Lexington Avenue, |
|
| November 13, 2023 |
EX-99.3 3 ss2696773ex9903.htm FORM OF LOCK-UP AGREEMENT Exhibit 3 FORM OF LOCK-UP AGREEMENT , 2023 Morgan Stanley & Co. LLC Cowen and Company, LLC Leerink Partners LLC Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Ge |
|
| November 13, 2023 |
EX-99.1 2 ss2696773ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 9, 2023, with respect to the common stock of Alpine Immune Sciences, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each |
|
| November 8, 2023 |
, as representatives of the several underwriters named therein. Exhibit 1.1 ALPINE IMMUNE SCIENCES, INC. 8,800,000 SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE 3,200,000 SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT November 6, 2023 November 6, 2023 Morgan Stanley & Co. LLC Cowen and Company, LLC Leerink Partners LLC as Representatives of the several Underwriters c/o Morgan Stanley & Co. LLC |
|
| November 8, 2023 |
Form of Prefunded Warrant to Purchase Common Stock Exhibit 4.1 ALPINE IMMUNE SCIENCES, INC. PREFUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. PF2023-[ ] Original Issue Date: [], 2023 Alpine Immune Sciences, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered ass |
|
| November 8, 2023 |
8,800,000 Shares of Common Stock 3,200,000 Pre-funded Warrants to Purchase Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271517 PROSPECTUS SUPPLEMENT (To Prospectus dated May 9, 2023) 8,800,000 Shares of Common Stock 3,200,000 Pre-funded Warrants to Purchase Shares of Common Stock We are offering 8,800,000 shares of our common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to 3,200,000 shares of common stock in |
|
| November 8, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Comm |
|
| November 7, 2023 |
8,800,000 Shares of Common Stock 3,200,000 Pre-funded Warrants to Purchase Shares of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated November 6, 2023 Relating to Preliminary Prospectus Supplement Dated November 6, 2023 Registration Statement No. |
|
| November 6, 2023 |
SUBJECT TO COMPLETION, DATED NOVEMBER 6, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-271517 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Comm |
|
| November 2, 2023 |
Exhibit 99.1 Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023 - Low-dose povetacicept (80 mg administered once every four weeks) was well tolerated during subcutaneous administration and reduced UPCR by greater than 50% in IgA nephropathy - - Higher dose po |
|
| November 2, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Comm |
|
| October 23, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of October 23, 2023, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with |
|
| October 23, 2023 |
ALPN / Alpine Immune Sciences Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G100 (CUSIP Number) October 11, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commi |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IMM |
|
| August 14, 2023 |
Exhibit 99.1 Alpine Immune Sciences Reports Second Quarter 2023 Financial Results -The Company will present preliminary data from RUBY-3 glomerulonephritis clinical study at the American Society of Nephrology Meeting in November 2023- SEATTLE, Washington - August 14, 2023 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative |
|
| August 14, 2023 |
As filed with the Securities and Exchange Commission on August 14, 2023 Registration No. |
|
| June 14, 2023 |
Amended and Restated Certificate of Incorporation of the Registrant, as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALPINE IMMUNE SCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Alpine Immune Sciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, as amended (the “DGCL”), hereby certifies as follows: DOES HEREBY CE |
|
| June 14, 2023 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commiss |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IM |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commissi |
|
| May 11, 2023 |
Alpine Immune Sciences, Inc. Up to $100,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271517 Prospectus supplement (to Prospectus dated May 9, 2023) Alpine Immune Sciences, Inc. Up to $100,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or TD Cowen, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the ac |
|
| May 11, 2023 |
Exhibit 10.2 ALPINE IMMUNE SCIENCES, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 1, 2020 (the “Effective Date”) between Alpine Immune Sciences, Inc. (the “Company”), and Remy Durand (“Executive”) (collectively referred to as the “Parties” or individually as a “Party”). R E C I T A L S WHEREAS, the Company desires to employ |
|
| May 11, 2023 |
Alpine Immune Sciences Reports First Quarter 2023 Financial Results Exhibit 99.1 Alpine Immune Sciences Reports First Quarter 2023 Financial Results SEATTLE, Washington., - May 11, 2023 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2023. “So far this year, we hav |
|
| May 5, 2023 |
ALPINE IMMUNE SCIENCES, INC. 188 East Blaine Street, Suite 200 Seattle, Washington 98102 ALPINE IMMUNE SCIENCES, INC. 188 East Blaine Street, Suite 200 Seattle, Washington 98102 May 5, 2023 VIA EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: Alpine Immune Sciences, Inc. Registration Statement on Form S-3 Filed April 28, 2023 File No. 333-271517 Acceleration Request Requested Date: May 9 |
|
| April 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Alpine Immune Sciences, Inc. |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 28, 2023 |
Exhibit 4.3 ALPINE IMMUNE SCIENCES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishmen |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commis |
|
| April 28, 2023 |
EX-1.2 3 alpn-ex1220230428.htm EX-1.2 Exhibit 1.2 ALPINE IMMUNE SCIENCES, INC. $100,000,000 OF SHARES OF COMMON STOCK SALES AGREEMENT April 28, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 To the addressee set forth above: Alpine Immune Sciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as |
|
| April 27, 2023 |
DEFA14A 1 defa14a2023meeting.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as pe |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| March 23, 2023 |
S-8 1 s-820230323evergreen.htm S-8 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 ALPINE IMMUNE SCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 20-8969493 (State or other jurisdiction of |
|
| March 23, 2023 |
EX-FILING FEES 2 alpn-ex10720230323evergre.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Alpine Immune Sciences, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37449 ALPINE IMMUNE SCIENCES, IN |
|
| March 23, 2023 |
List of subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF ALPINE IMMUNE SCIENCES, INC. Name of Subsidiary State or other Jurisdiction of Incorporation AIS Operating Co., Inc. Delaware Alpine Immune Sciences Australia PTY LTD Australia |
|
| March 23, 2023 |
S-8 1 s-820230323inducement.htm S-8 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8969493 (State or other jurisdiction o |
|
| March 23, 2023 |
Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results •RUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2 2023 •Initial data from both basket studies are anticipated by the end of 20 |
|
| March 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Alpine Immune Sciences, Inc. |
|
| March 23, 2023 |
Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Alpine Immune Sciences, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. The general terms and provisions of our common stock are summarized below. This summary d |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commis |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 02083G100 (CUSIP Num |
|
| February 14, 2023 |
ALPN / Alpine Immune Sciences Inc / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALPINE IMMUNE SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designat |
|
| February 14, 2023 |
ALPN / Alpine Immune Sciences Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d19sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALPINE IMMUNE SCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stat |
|
| February 14, 2023 |
ALPN / Alpine Immune Sciences Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
ALPN / Alpine Immune Sciences Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
SC 13G/A 1 p23-0349sc13ga.htm ALPINE IMMUNE SCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| February 13, 2023 |
ALPN / Alpine Immune Sciences Inc / Omega Fund VI, L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2) Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2022 (Date of Even |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Comm |
|
| January 26, 2023 |
Amended and Restated Bylaws of the Registrant Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ALPINE IMMUNE SCIENCES, INC. ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Alpine Immune Sciences, Inc. (the “Corporation”) shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “certificate of incorporation”). 1.2 OTHER OFFICES. The Corporation may at any time e |
|
| November 14, 2022 |
Form of Stand-Alone Inducement Stock Option Grant Exhibit 10.1 ALPINE IMMUNE SCIENCES, INC. STAND-ALONE INDUCEMENT STOCK OPTION GRANT NOTICE OF GRANT OF STOCK OPTION This grant (the ?Option?) shall be governed by this Notice of Grant of Stock Option (the ?Notice of Grant?) and the Terms and Conditions of Stock Option Grant (the ?Terms and Conditions?), attached hereto as Exhibit A (together, the ?Agreement?). Terms not otherwise defined in the No |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPIN |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Com |
|
| November 14, 2022 |
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results SEATTLE, Washington., - November 14, 2022 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results fo |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Comm |
|
| October 24, 2022 |
Exhibit 99.1 Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2) - Company?s primary focus will be the pursuit of expedited development plans for ALPN-303 in multiple autoimmune and inflammatory indications - SEATTLE ? (BUSINESS WIRE) ? Oct. 24, 2022 ? Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused o |
|
| October 3, 2022 |
ALPN / Alpine Immune Sciences Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ALPINE IMMUNE SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) September 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| October 3, 2022 |
ALPN / Alpine Immune Sciences Inc / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) September 23, 2022 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designat |
|
| October 3, 2022 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| September 30, 2022 |
ALPN / Alpine Immune Sciences Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 27, 2022 |
ALPN / Alpine Immune Sciences Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 6 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G100 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) |
|
| September 27, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated September 23, 2022, with respect to the common stock of Alpine Immune Sciences, Inc. |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) Decheng Capital China Life Sciences USD Fund III, L.P. Ugland House, PO Box 309, Grand Cayman KY1-1104, Cayman |
|
| September 27, 2022 |
ALPN / Alpine Immune Sciences Inc / Alpine ImmunoSciences, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) Dr. Mitchell H. Gold 600 Stewart Street, Suite 1503 Seattle, Washington 98101 Telephone: (206) 441-5064 (Name, Address and Te |
|
| September 27, 2022 |
Execution Version LOCK-UP AGREEMENT September 20, 2022 Morgan Stanley & Co. LLC SVB Securities LLC Cowen and Company, LLC Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: The undersigned understands that Morgan |
|
| September 21, 2022 |
13,606,000 Shares of Common Stock 424B5 1 a424b52021finalprosupp.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-256107 PROSPECTUS SUPPLEMENT (To Prospectus dated May 20, 2021) 13,606,000 Shares of Common Stock We are offering 13,606,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Market under the symbol “ALPN.” The last reported sale price of our common stock on the |
|
| September 21, 2022 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Co |
|
| September 21, 2022 |
Execution Version ALPINE IMMUNE SCIENCES, INC. 13,606,000 SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT September 20, 2022 September 20, 2022 Morgan Stanley & Co. LLC SVB Securities LLC Cowen and Company, LLC as Representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o SVB Securities LLC 1301 Avenue of the Americ |
|
| September 20, 2022 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 20, 2022 424B5 1 a424b52021prosuppprojectyo.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-256107 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectu |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Co |
|
| August 11, 2022 |
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results SEATTLE, Wash., - August 11, 2022 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial result |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commi |
|
| August 11, 2022 |
Employment Agreement, dated as of May 27, 2022, by and between the Registrant and Andrew Sandler ALPINE IMMUNE SCIENCES, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into between Alpine Immune Sciences, Inc. (the ?Company?), and Andrew Sandler (?Executive?) (collectively referred to as the ?Parties? or individually as a ?Party?). R E C I T A L S WHEREAS, the Company desires to employ Executive as its Chief Medical Officer (?CMO?), and to |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IMM |
|
| August 11, 2022 |
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| August 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commis |
|
| August 9, 2022 |
Leading the Next Evolution of Immunotherapies August 2022 Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and incl |
|
| July 19, 2022 |
Exhibit 99.1 Alpine Immune Sciences Appoints J?rn Drappa, MD, PhD, to Board of Directors - 20-year industry veteran with extensive global clinical development leadership experience in autoimmune and inflammatory diseases - Seattle, WA ? July 19, 2022?Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commiss |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commiss |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commissi |
|
| May 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commissi |
|
| May 24, 2022 |
Exhibit 99.1 FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab SEATTLE, Wash., - May 24, 2022 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that the U.S. Food and Drug A |
|
| May 12, 2022 |
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results SEATTLE, Wash., - May 12, 2022 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results fo |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IM |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commissi |
|
| April 29, 2022 |
Definitive Proxy Statement on Schedule 14A DEF 14A 1 defproxy2021.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| April 29, 2022 |
DEFA14A 1 defa14a2021.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| April 22, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 02083G100 (CUSIP Number) April 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| March 17, 2022 |
S-8 1 s-82022planincrease.htm S-8 As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 ALPINE IMMUNE SCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 20-8969493 (State or other jurisdiction of |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37449 ALPINE IMMUNE SCIENCES, IN |
|
| March 17, 2022 |
Exhibit 10.30 Execution Version CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [***]. LICENSE AND COLLABORATION AGREEMENT This LICENSE AND COLLABORATION AGREEMENT (the ?Agreement?) is entered into as of December 15, 2021 (the ?Effective Date?) by and |
|
| March 17, 2022 |
EX-FILING FEES 2 alpn-ex10720220317.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Alpine Immune Sciences, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee |
|
| March 17, 2022 |
Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results - Execution across three clinical-stage programs and addition of $176 million in committed cash in 2021 from partnerships and financing to further advance pipeline - - Davoceticept monotherapy dose escalation data to be presented at 2022 AACR Annual Meeting - - ALPN-303 pha |
|
| March 17, 2022 |
Exhibit 10.13 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Zelanna Goldberg (?Employee?) and Alpine Immune Sciences, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). RECITALS WHEREAS, Employee was employed by the Company pursuant to that certain Executive Employment Agreement be |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commis |
|
| March 17, 2022 |
Exhibit 10.31 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this ?Agreement?) is dated as of December 15, 2021, by and between Alpine Immune Sciences, Inc., a Delaware corporation (the ?Company?), and Horizon Therapeutics Ireland DAC, an Irish company (the ?Purchaser?). RECITALS The Company and the Purchaser are each executing and delivering this Agreement in reliance upon the exemption |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G 100 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Te |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 02083G100 (CUSIP Number) Decem |
|
| February 14, 2022 |
ALPN / Alpine Immune Sciences Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
ALPN / Alpine Immune Sciences Inc / Omega Fund VI, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1) Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G100 (CUSIP Number) December 31, 2021 (Date of Event Which R |
|
| February 14, 2022 |
SC 13G 1 tm226449d2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 02083G100 (CUSIP Number) Laura Tse 3000 Sand Hill Road, Building 2, Suite 110 Menlo Park, CA 94025, USA 650-23 |
|
| December 16, 2021 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Com |
|
| November 22, 2021 |
Alpine Immune Sciences, Inc. 9,680,844 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-260971 Alpine Immune Sciences, Inc. 9,680,844 Shares of Common Stock This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 8 of up to 9,680,844 shares of our common stock, including shares issuable upon the exercise of |
|
| November 17, 2021 |
ALPINE IMMUNE SCIENCES, INC. 188 East Blaine Street, Suite 200 Seattle, Washington 98102 CORRESP 1 filename1.htm ALPINE IMMUNE SCIENCES, INC. 188 East Blaine Street, Suite 200 Seattle, Washington 98102 November 17, 2021 VIA EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: Alpine Immune Sciences, Inc. Registration Statement on Form S-3 Filed November 10, 2021 File No. 333-260971 Acceleration R |
|
| November 12, 2021 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| November 12, 2021 |
ALPN / Alpine Immune Sciences Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 02083G100 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC 601 Lexington Avenue, 54th Floor New York |
|
| November 10, 2021 |
Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results - Recent private placement enables expansion and acceleration of development plans across the portfolio - - Plenary presentation for ALPN-303 at the American College of Rheumatology Convergence 2021 Annual Meeting highlighting best in class potential - SEATTLE, WA - November 10, 2021 - Al |
|
| November 10, 2021 |
As filed with the Securities and Exchange Commission on November 10, 2021 Registration No. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPIN |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Com |
|
| October 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commi |
|
| September 30, 2021 |
Leading the Next Evolution of Immunotherapies 188 E. Blaine Street, Ste 200 Seattle, WA 98102 O 206 788 4545 September 30, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington D.C. 20549 Attention: Ms. Sasha Parikh Mr. Kevin Vaughn Re: Alpine Immune Sciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 18, 2021 File No. 001-37449 Dear Ms. Parik |
|
| September 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALPINE IMMUNE SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) Decheng Capital China Life Sciences USD Fund III, L.P. Ugland House, PO Box 309, Grand Cayman KY1-1104, Cayman |
|
| September 21, 2021 |
ALPINE IMMUNE SCIENCES, INC. PREFUNDED WARRANT TO PURCHASE COMMON STOCK Exhibit 99.B THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION ST |
|
| September 21, 2021 |
ALPN / Alpine Immune Sciences Inc / Frazier Life Sciences VIII, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02083G 100 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Te |
|
| September 21, 2021 |
ALPN / Alpine Immune Sciences Inc / Alpine ImmunoSciences, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Alpine Immune Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 02083G100 (CUSIP Number) Dr. Mitchell H. Gold 600 Stewart Street, Suite 1503 Seattle, Washington 98101 Telephone: (206) 441-5064 (Name, Address and Te |
|
| September 21, 2021 |
Exhibit 99.A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of Common Stock of Alpine Immune Systems, Inc. Date: September 21, 2021 FRAZIER LIFE SCIENCES VIII, L.P. By FHM Life Sciences VII |
|
| September 15, 2021 |
Alpine Immune Sciences Announces $91 Million Private Placement Exhibit 99.1 Alpine Immune Sciences Announces $91 Million Private Placement SEATTLE, September 15, 2021 ? Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common stock an |
|
| September 15, 2021 |
, 2021, by and among the Company and the Purchasers Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of September 14, 2021, by and among Alpine Immune Sciences, Inc., a Delaware corporation (the ?Company?), and the several purchasers signatory hereto (each a ?Purchaser? and collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Agreement |
|
| September 15, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 14, 2021, by and among Alpine Immune Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively, the ?Purchasers?). RECITALS A. The Com |
|
| September 15, 2021 |
Form of Prefunded Warrant to Purchase Common Stock Exhibit 10.3 THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION ST |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2021 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Co |
|
| September 15, 2021 |
Exchange Agreement, dated September 14, 2021, by and between Exhibit 10.4 September 14, 2021 Mitchell H. Gold, M.D. Executive Chairman and Chief Executive Officer Alpine Immune Sciences, Inc. 188 E. Blaine Street, Suite 200 Seattle, WA 98102 Re: 3(a)(9) Exchange Agreement Dear Dr. Gold: This letter agreement (the ?Agreement?) confirms the agreement of Alpine Immune Sciences, Inc., a Delaware corporation (the ?Company?), and the holder of the Common Stock li |
|
| August 10, 2021 |
Form of Stand-Alone Inducement Stock Option Grant Exhibit 4.4 ALPINE IMMUNE SCIENCES, INC. STAND-ALONE INDUCEMENT STOCK OPTION GRANT NOTICE OF GRANT OF STOCK OPTION This grant (the ?Option?) shall be governed by this Notice of Grant of Stock Option (the ?Notice of Grant?) and the Terms and Conditions of Stock Option Grant (the ?Terms and Conditions?), attached hereto as Exhibit A (together, the ?Agreement?). Terms not otherwise defined in the Not |
|
| August 10, 2021 |
Form of Stand-Alone Inducement Stock Option Grant between the Company and Zelanna Goldberg Exhibit 10.1 ALPINE IMMUNE SCIENCES, INC. STAND-ALONE INDUCEMENT STOCK OPTION GRANT NOTICE OF GRANT OF STOCK OPTION This grant (the ?Option?) shall be governed by this Notice of Grant of Stock Option (the ?Notice of Grant?) and the Terms and Conditions of Stock Option Grant (the ?Terms and Conditions?), attached hereto as Exhibit A (together, the ?Agreement?). Terms not otherwise defined in the No |
|
| August 10, 2021 |
As filed with the Securities and Exchange Commission on August 10, 2021 Registration No. |
|
| August 10, 2021 |
Employment Agreement, dated as of June 1, 2021, by and between the Registrant and Zelanna Goldberg Exhibit 10.2 ALPINE IMMUNE SCIENCES, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of June 1, 2021 (the ?Effective Date?) between Alpine Immune Sciences, Inc. (the ?Company?), and Zelanna Goldberg (?Executive?) (collectively referred to as the ?Parties? or individually as a ?Party?). R E C I T A L S WHEREAS, the Company desires to empl |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IMM |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commi |
|
| August 10, 2021 |
Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results - Conference call and webcast today at 4:30 p.m. ET - SEATTLE, WA - August 10, 2021 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a |
|
| July 2, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2021 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commissi |
|
| July 2, 2021 |
$75,000,000 Alpine Immune Sciences, Inc. Common Stock PROSPECTUS SUPPLEMENT (to Prospectus Dated May 20, 2021) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| July 2, 2021 |
, 2021, between Alpine Immune Sciences, Inc. and Cowen and Company, LLC. Exhibit 1.1 ALPINE IMMUNE SCIENCES, INC. $75,000,000 OF SHARES OF COMMON STOCK SALES AGREEMENT July 2, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Alpine Immune Sciences, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company |
|
| June 10, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commissi |
|
| May 20, 2021 |
Alpine Immune Sciences, Inc. 7,709,416 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-244409 Alpine Immune Sciences, Inc. 7,709,416 Shares of Common Stock This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 8 of up to 7,709,416 shares of our common stock, including shares issuable upon the exercise of |
|
| May 18, 2021 |
ALPINE IMMUNE SCIENCES, INC. 188 East Blaine Street, Suite 200 Seattle, Washington 98102 ALPINE IMMUNE SCIENCES, INC. 188 East Blaine Street, Suite 200 Seattle, Washington 98102 May 18, 2021 VIA EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Re: Alpine Immune Sciences, Inc. Registration Statement on Form S-3 Filed May 14, 2021 File No. 333-256107 Acceleration Request Requested Date: May 20, |
|
| May 14, 2021 |
As filed with the Securities and Exchange Commission on May 13, 2021 As filed with the Securities and Exchange Commission on May 13, 2021 Registration No. |
|
| May 14, 2021 |
Exhibit 4.3 ALPINE IMMUNE SCIENCES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishmen |
|
| May 14, 2021 |
As filed with the Securities and Exchange Commission on May 13, 2021 Registration No. |
|
| May 14, 2021 |
POS AM 1 s-3sx1conversionof2020pipe.htm POS AM As filed with the Securities and Exchange Commission on May 13, 2021 Registration No. 333-244409 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in it |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 ALPINE IMMUNE SCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commission F |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IM |
|
| May 13, 2021 |
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results SEATTLE, WA - May 13, 2021 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fi |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| March 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 ALPINE IMMUNE SCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37449 20-8969493 (State or other jurisdiction of incorporation) (Commission |
